Treatment-emergent nonhematologic AEs of any grade occurring in ≥20% of patients (N = 44)
| . | All grades, n (%) . | Carfilzomib-related, n (%) . |
|---|---|---|
| Diarrhea | 29 (66) | 11 (25) |
| Nausea | 26 (59) | 20 (45) |
| Fatigue | 24 (55) | 21 (48) |
| Headache | 23 (52) | 19 (43) |
| Constipation | 22 (50) | 11 (25) |
| Upper respiratory infection | 18 (41) | 18 (41) |
| Peripheral edema | 17 (39) | 10 (23) |
| Dyspnea | 16 (36) | 8 (18) |
| Rash | 16 (36) | 6 (14) |
| Arthralgia | 16 (36) | 4 (9) |
| Hypertension | 12 (27) | 12 (27) |
| Heart failure* | 11 (25) | 7 (16) |
| . | All grades, n (%) . | Carfilzomib-related, n (%) . |
|---|---|---|
| Diarrhea | 29 (66) | 11 (25) |
| Nausea | 26 (59) | 20 (45) |
| Fatigue | 24 (55) | 21 (48) |
| Headache | 23 (52) | 19 (43) |
| Constipation | 22 (50) | 11 (25) |
| Upper respiratory infection | 18 (41) | 18 (41) |
| Peripheral edema | 17 (39) | 10 (23) |
| Dyspnea | 16 (36) | 8 (18) |
| Rash | 16 (36) | 6 (14) |
| Arthralgia | 16 (36) | 4 (9) |
| Hypertension | 12 (27) | 12 (27) |
| Heart failure* | 11 (25) | 7 (16) |
Heart failure includes LV systolic dysfunction, pulmonary edema, and/or other criteria.